2024

• Tyligand Bioscience Announces First Patient Dosed in Phase 1/2 Clinical Trial of TSN1611, a Selective and Orally Bioavailable KRAS G12D Inhibitor
• Tyligand Bioscience to Present Preclinical Study Results of TSN1611, a potent, selective, and orally bioavailable KRAS G12D Inhibitor at AACR 2024, following FDA’s IND Clearance